ArticleAmerican heart journal plus : cardiology research and practice2026
Cardiovascular outcomes with semaglutide versus tirzepatide in patients with obesity and atherosclerotic cardiovascular disease without diabetes.
Article in American heart journal plus : cardiology research and practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Comparative cardiovascular data on glucagon-like peptide-1 (GLP-1) agonists versus dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 agonists in atherosclerotic cardiovascular disease (ASCVD) without diabetes are limited. Methods: This propensity score-matched retrospective TriNetX study compared adults aged ≥45 years with body mass index ≥27 kg/m Results: After matching, 5665 patients were analyzed per group. No statistically significant differences were observed between semaglutide and tirzepatide in 5-point MACE (19.5% vs 17.1%; HR 1.03; 95% CI 0.94-1.12), 3-point MACE (17.4% vs 15.4%; HR 1.04; 95% CI 0.95-1.14), or any individual component. Conclusions: Semaglutide and tirzepatide were associated with similar cardiovascular outcomes. Prospective head-to-head trials are warranted to validate these results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.